Back to results
US 11,484,558 B2Granted
Epizootic hemorrhagic disease virus—tel aviv university (EHDV-TAU)—oncolytic virus for treating cancer
AssigneeRamot at Tel-Aviv University Ltd.
InventorsMarcelo Ehrlich, Eran Bacharach, Ben Shai, Oded Danziger
Life of this patent
Estimating the term…
Abstract
The present invention relates to a unique oncolytic virus, Epizootic Hemorrhagic Disease virus-Tel Aviv University (EHDV-TAU), and to methods and pharmaceutical compositions comprising thereof for preventing or treating cancer exhibiting an alteration in interferon signaling and/or the innate immune antiviral response.
Claims10
A method for treating cancer, comprising:
- administering to a subject in need thereof a pharmaceutical composition comprising Epizootic Hemorrhagic Disease virus-Tel Aviv University LNCaP (EHDV-TAU-LNCaP) comprising the RNA sequence set forth in SEQ ID NO:
- 3, wherein the subject in need thereof is a subject having cancer exhibiting deficient interferon signaling.
The oncolytic EHDV-TAU-LNCaP virus comprising the RNA sequence as set forth in SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.